Wedbush Has Optimistic Outlook of KNSA Q1 Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Research analysts at Wedbush increased their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a report released on Tuesday, February 25th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $0.31 for the quarter, up from their prior estimate of $0.10. Wedbush currently has a “Outperform” rating and a $34.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.69 EPS, FY2026 earnings at $2.55 EPS and FY2027 earnings at $3.24 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter last year, the business posted $0.35 EPS. The business’s revenue was up 46.9% compared to the same quarter last year.

Separately, JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA opened at $20.28 on Thursday. Kiniksa Pharmaceuticals has a 1-year low of $16.56 and a 1-year high of $28.15. The company has a market capitalization of $1.46 billion, a P/E ratio of -144.85 and a beta of 0.32. The firm’s 50 day simple moving average is $19.66 and its 200 day simple moving average is $22.55.

Institutional Trading of Kiniksa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Braidwell LP raised its holdings in Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after buying an additional 557,934 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock valued at $15,737,000 after acquiring an additional 54,361 shares during the last quarter. Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals by 50.9% during the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock valued at $15,422,000 after acquiring an additional 263,146 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock worth $15,262,000 after purchasing an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in shares of Kiniksa Pharmaceuticals by 1.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company’s stock worth $15,141,000 after purchasing an additional 10,209 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,092 shares of company stock valued at $745,589. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.